FDA approves first epoetin alfa biosimilar for the treatment of anemia

SILVER SPRING, Md., May 15, 2018 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine...